Increased resistance to nitrogen mustards and antifolates following in vitro selection of murine fibroblasts and primary hematopoietic cells transduced with a bicistronic retroviral vector expressing the rat glutathione S-transferase A3 and a mutant dihydrofolate reductase

Cancer Gene Therapy

Volumn 10, Issue 8, 2003, Pages 637-646

  Belzile, Jean Philippe ^a   Karatzas, Antonis ^a   Shiu, Hoi Ying ^a   Létourneau, Sylvain ^a   Palerme, Jean Sébastien ^a   Cournoyer, Denis ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Chemoprotection; DHFR; Fibroblasts; GST; Hematopoietic cells; Selection

Indexed keywords

CHLORAMBUCIL; CHLORMETHINE DERIVATIVE; DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; GALACTOSE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE A3; ISOENZYME; MELPHALAN; MUTANT PROTEIN; PEROXIDASE; PROTEIN INHIBITOR; RECOMBINANT ENZYME; RETROVIRUS VECTOR; TRIMETREXATE GLUCURONATE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ARTICLE; BICISTRONIC RETROVIRUS VECTOR; CELL PROTECTION; CELL SELECTION; CELL SURVIVAL; CHEMOPROTECTION; CONTROLLED STUDY; DRUG REEXPOSURE; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; FIBROBLAST; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; MOUSE; NONHUMAN; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; TRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; DRUG RESISTANCE; FIBROBLASTS; FOLIC ACID ANTAGONISTS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLUTATHIONE TRANSFERASE; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; NIH 3T3 CELLS; NITROGEN MUSTARD COMPOUNDS; PROTEIN ISOFORMS; RATS; RETROVIRIDAE; TETRAHYDROFOLATE DEHYDROGENASE; TRANSDUCTION, GENETIC;

ANIMALIA; BRASSICACEAE; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0042733390     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700619     Document Type: Article

References (67)

1. Sorrentino BP, McDonagh KT, Woods D, et al. Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice. Blood. 1995;86:491-501.
2. Licht T, Aksentijevich I, Gottesman MM, et al. Efficient expression of functional human MDR1 gene in murine bone marrow after retroviral transduction of purified hematopoietic stem cells. Blood. 1995;86:111-121.
3. Carpinteiro A, Peinert S, Ostertag W, et al. Genetic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell transplantation in mice. Int J Cancer. 2002;98:785-792.
4. Machiels JP, Govaerts AS, Guillaume T, et al. Retrovirus-mediated gene transfer of the human multidrug resistance-associated protein into hematopoietic cells protects mice from chemotherapy-induced leukopenia. Hum Gene Ther. 1999;10:801-811.
5. Zhao SC, Li MX, Banerjee D, et al. Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther. 1994;1:27-33.
6. Spencer HT, Sleep SE, Rehg JE, et al. A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood. 1996;87:2579-2587.
7. Matsunaga T, Sakamaki S, Kuga T, et al. GST-pi gene-transduced hematopoietic progenitor cell transplantation overcomes the bone marrow toxicity of cyclophosphamide in mice. Hum Gene Ther. 2000;11:1671-1681.
8. Maze R, Kapur R, Kelley MR, et al. Reversal of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced severe immunodeficiency by transduction of murine long-lived hemopoietic progenitor cells using O6-methylguanine DNA methyltransferase complementary DNA. J Immunol. 1997;158: 1006-1013.
9. Davis BM, Reese JS, Koc ON, et al. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 1997;57:5093-5099.
10. Harris LC, Marathi UK, Edwards CC, et al. Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity. Clin Cancer Res. 1995;1:1359-1368.
11. Jedlitschky G, Leier I, Buchholz U, et al. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996;56:988-994.
12. Barnouin K, Leier I, Jedlitschky G, et al. Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer. 1998;77:201-209.
13. Mannervik B, Jensson H. Binary combinations of four protein subunits with different catalytic specificities explain the relationship between six basic glutathione S-transferases in rat liver cytosol. J Biol Chem. 1982;257:9909-9912.
14. Hengstler JG, Bottger T, Tanner B, et al. Resistance factors in colon cancer tissue and the adjacent normal colon tissue: glutathione S-transferases alpha and pi, glutathione and aldehyde dehydrogenase. Cancer Lett. 1998;128:105-112.
15. Ribrag V, Massade L, Faussat AM, et al. Drug resistance mechanisms in chronic lymphocytic leukemia. Leukemia. 1996;10:1944-1949.
16. Sargent JM, Williamson C, Hall AG, et al. Evidence for the involvement of the glutathione pathway in drug resistance in AML. Adv Exp Med Biol. 1999;457:205-209.
17. Kodera Y, Isobe K, Yamauchi M, et al. Expression of glutathione-S-transferases alpha and pi in gastric cancer: a correlation with cisplatin resistance. Cancer Chemother Pharmacol. 1994;34:203-208.
18. Buller AL, Clapper ML, Tew KD. Glutathione S-transferases in nitrogen mustard-resistant and -sensitive cell lines. Mol Pharmacol. 1987;31:575-578.
19. Clapper ML, Kuzmich S, Seestaller LM, et al. Time course of glutathione S-transferase elevation in Walker mammary carcinoma cells following chlorambucil exposure. Biochem Pharmacol. 1993;45:683-690.
20. Murray GI, Taylor VE, McKay JA, et al. The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. J Pathol. 1995;177:147-152.
21. Raha A, Tew KD. Glutathione S-transferases. Cancer Treat Res. 1996;87:83-122.
22. Schecter RL, Alaoui-Jamali MA, Woo A, et al. Expression of a rat glutathione-S-transferase complementary DNA in rat mammary carcinoma cells: impact upon alkylator-induced toxicity. Cancer Res. 1993;53:4900-4906.
23. Black SM, Beggs JD, Hayes JD, et al. Expression of human glutathione S-transferases in Saccharomyces cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil. Biochem J. 1990;268:309-315.
24. Moscow JA, Townsend AJ, Cowan KH. Elevation of pi class glutathione S-transferase activity in human breast cancer cells by transfection of the GST pi gene and its effect on sensitivity to toxins. Mol Pharmacol. 1989; 36:22-28.
25. Puchalski RB, Fahl WE. Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents. Proc Natl Acad Sci USA. 1990;87:2443-2447.
26. Letourneau S, Greenbaum M, Cournoyer D. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells. Hum Gene Ther. 1996;7:831-840.
27. Greenbaum M, Letourneau S, Assar H, et al. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers alkylating drug resistance in NIH 3T3 mouse fibroblasts. Cancer Res. 1994;54:4442-4447.
28. Abonour R, Williams DA, Einhorn L, et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med. 2000;6:652-658.
29. Allay JA, Galipeau J, Blakley RL, et al. Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells. Stem Cells. 1998;16(Suppl 1):223-233.
30. Hanania EG, Giles RE, Kavanagh J, et al. Results of MDR1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA. 1996;93: 15346-15351.
31. Hesdorffer C, Ayello J, Ward M, et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol. 1998;16:165-172.
32. Cowan KH, Moscow JA, Huang H, et al. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res. 1999;5:1619-1628.
33. Moscow JA, Huang H, Carter C, et al. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood. 1999;94:52-61.
34. Flasshove M, Banerjee D, Mineishi S, et al. Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood. 1995;85:566-574.
35. Flasshove M, Banerjee D, Leonard JP, et al. Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. Hum Gene Ther. 1998;9:63-71.
36. Takebe N, Xu LC, MacKenzie KL, et al. Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene. Cancer Gene Ther. 2002;9:308-320.
37. Havenga M, Valerio D, Hoogerbrugge P, et al. In vivo methotrexate selection of murine hemopoietic cells transduced with a retroviral vector for Gaucher disease. Gene Therapy. 1999;6:1661-1669.
38. Warlick CA, Diers MD, Wagner JE, et al. In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model. J Pharmacol Exp Ther. 2002;300:50-56.
39. Allay JA, Persons DA, Galipeau J, et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med. 1998;4:1136-1143.
40. Koo HM, Brown AM, Kaufman RJ, et al. A spleen necrosis virus-based retroviral vector which expresses two genes from a dicistronic mRNA. Virology. 1992;186:669-675.
41. Chen BF, Hwang LH, Chen DS. Characterization of a bicistronic retroviral vector composed of the swine vesicular disease virus internal ribosome entry site. J Virol. 1993;67:2142-2148.
42. Aran JM, Gottesman MM, Pastan I. Drug-selected coexpression of human glucocerebrosidase and P-glycoprotein using a bicistronic vector. Proc Natl Acad Sci USA. 1994;91:3176-3180.
43. Sugimoto Y, Aksentijevich I, Gottesman MM, et al. Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site. Biotechnology (NY). 1994;12:694-698.
44. Galipeau J, Benaim E, Spencer HT, et al. A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs. Hum Gene Ther. 1997;8:1773-1783.
45. Letourneau S, Palerme JS, Delisle JS, et al. Coexpression of rat glutathione S-transferase A3 and human cytidine deaminase by a bicistronic retroviral vector confers in vitro resistance to nitrogen mustards and cytosine arabinoside in murine fibroblasts. Cancer Gene Ther. 2000; 7:757-765.
46. Eliopoulos N, Bovenzi V, Le NL, et al. Retroviral transfer and long-term expression of human cytidine deaminase cDNA in hematopoietic cells following transplantation in mice. Gene Therapy. 1998;5:1545-1551.
47. Southern PJ, Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet. 1982;1:327-341.
48. Bodine DM, McDonagh KT, Brandt SJ, et al. Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. Proc Natl Acad Sci USA. 1990;87:3738-3742.
49. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 1990;10:4239-4242.
50. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol. 1994;68:510-516.
51. Bukrinsky MI, Haggerty S, Dempsey MP, et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature. 1993;365:666-669.
52. Fletcher TM, Brichacek B, Sharova N, et al. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J. 1996;15:6155-6165.
53. Miyoshi H, Smith KA, Mosier DE, et al. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science. 1999;283: 682-686.
54. Bunting KD, Galipeau J, Topham D, et al. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood. 1998;92:2269-2279.
55. Bunting KD, Galipeau J, Topham D, et al. Effects of retroviral-mediated MDR1 expression on hematopoietic stem cell self-renewal and differentiation in culture. Ann NY Acad Sci. 1999;872:125-140.
56. Sellers SE, Tisdale JF, Agricola BA, et al. The effect of multidrug-resistance I gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells. Blood. 2001;97:1888-1891.
57. Lewis WS, Cody V, Galitsky N, et al. Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers. J Biol Chem. 1995;270: 5057-5064.
58. Chunduru SK, Cody V, Luft JR, et al. Methotrexate-resistant variants of human dihydrofolate reductase. Effects of Phe31 substitutions. J Biol Chem. 1994;269:9547-9555.
59. Jansen G, Mauritz RM, Assaraf YG, et al. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and -resistant leukemia cells. Adv Enzyme Regul. 1997;37:59-76.
60. Moscow JA, Connolly T, Myers TG, et al. Reduced folate carrier gene (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines. Int J Cancer. 1997;72:184-190.
61. Blau CA, Neff T, Papayannopoulou T. The hematological effects of folate analogs: implications for using the dihydrofolate reductase gene for in vivo selection. Hum Gene Ther. 1996;7:2069-2078.
62. Allay JA, Spencer HT, Wilkinson SL, et al. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood. 1997;90: 3546-3554.
63. Baer HP, Serignese V, Moorji A, et al. In vivo effectiveness of several nucleoside transport inhibitors in mice and hamsters. Naunyn Schmiedebergs Arch Pharmacol. 1991;343:365-369.
64. Griffiths M, Beaumont N, Yao SY, et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med. 1997;3:89-93.
65. Belt JA, Marina NM, Phelps DA, et al. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul. 1993;33:235-252.
66. Tura S, Fiacchini M, Zinzani PL, et al. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. J Clin Oncol. 1993;11:925-930.
67. Delwail V, Jais JP, Colonna P, et al. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol. 2002;118:189-194.